ES2908424T3 - Forma cristalina y tipo de sal del compuesto triazolopirimidina y método de preparación de la misma - Google Patents

Forma cristalina y tipo de sal del compuesto triazolopirimidina y método de preparación de la misma Download PDF

Info

Publication number
ES2908424T3
ES2908424T3 ES19793622T ES19793622T ES2908424T3 ES 2908424 T3 ES2908424 T3 ES 2908424T3 ES 19793622 T ES19793622 T ES 19793622T ES 19793622 T ES19793622 T ES 19793622T ES 2908424 T3 ES2908424 T3 ES 2908424T3
Authority
ES
Spain
Prior art keywords
compound
crystalline form
added
equiv
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19793622T
Other languages
English (en)
Spanish (es)
Inventor
Kevin X Chen
Yanxin Yu
Xinde Chen
Li Zhang
Zhaoguo Chen
Cheng Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Application granted granted Critical
Publication of ES2908424T3 publication Critical patent/ES2908424T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19793622T 2018-04-28 2019-04-28 Forma cristalina y tipo de sal del compuesto triazolopirimidina y método de preparación de la misma Active ES2908424T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810399876 2018-04-28
PCT/CN2019/084822 WO2019206336A1 (zh) 2018-04-28 2019-04-28 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Publications (1)

Publication Number Publication Date
ES2908424T3 true ES2908424T3 (es) 2022-04-29

Family

ID=68294924

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19793622T Active ES2908424T3 (es) 2018-04-28 2019-04-28 Forma cristalina y tipo de sal del compuesto triazolopirimidina y método de preparación de la misma

Country Status (9)

Country Link
US (1) US11649239B2 (enExample)
EP (1) EP3766884B1 (enExample)
JP (1) JP7406691B2 (enExample)
CN (1) CN112105617B (enExample)
DK (1) DK3766884T3 (enExample)
ES (1) ES2908424T3 (enExample)
PL (1) PL3766884T3 (enExample)
PT (1) PT3766884T (enExample)
WO (1) WO2019206336A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11649239B2 (en) * 2018-04-28 2023-05-16 Medshine Discovery Inc. Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MX2022002219A (es) * 2019-08-26 2022-06-14 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b.
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284737C (en) 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2003272886A1 (en) 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
JP7065113B2 (ja) 2017-04-07 2022-05-11 南京明徳新薬研発有限公司 Ａ２Ａ受容体阻害剤としての［１，２，４］トリアゾロ［１，５－ｃ］ピリミジン誘導体
US11649239B2 (en) * 2018-04-28 2023-05-16 Medshine Discovery Inc. Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)

Also Published As

Publication number Publication date
EP3766884A1 (en) 2021-01-20
PL3766884T3 (pl) 2022-07-18
CN112105617A (zh) 2020-12-18
US20210094957A1 (en) 2021-04-01
WO2019206336A1 (zh) 2019-10-31
PT3766884T (pt) 2022-03-31
JP2021522335A (ja) 2021-08-30
EP3766884A4 (en) 2021-03-31
EP3766884B1 (en) 2022-02-09
JP7406691B2 (ja) 2023-12-28
DK3766884T3 (da) 2022-03-28
CN112105617B (zh) 2022-04-05
US11649239B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
CN112912077B (zh) 用于治疗三阴性乳腺癌的组合疗法
CN112552302B (zh) 取代的芳香稠合环衍生物及其组合物及用途
US11649239B2 (en) Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
ES2415863T3 (es) Heterociclos sustituidos como inhibidores de Janus Quinasas
WO2023045816A1 (zh) 作为axl抑制剂的苯并环庚烷类化合物
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
ES2856848T3 (es) Nuevos compuestos de 3,5-disustituida-3H-imidazo[4,5-B] biridina y 3,5-disustituida-3H-[1,2,3] triazolo[4,5-B] piridina como moduladores de proteína cinasas C-MET
PT2663564E (pt) Composto de imidazo[4,5-c]quinolin-2-ona e a sua utilização como inibidor dual de quinase pi3/mtor
CN107840846A (zh) 一种含嘧啶环的化合物、egfr抑制剂及其应用
WO2013134252A1 (en) 2-amino, 6 - phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
WO2021252679A1 (en) 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors
ES2908498T3 (es) Análogo de pirido[1,2-a]pirimidona, forma cristalina del mismo, intermedio del mismo y método de preparación del mismo
WO2021252681A1 (en) Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors
CN111196814B (zh) 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
WO2017088746A1 (zh) 新的表皮生长因子受体抑制剂及其应用
CN103936762B (zh) 吗啉并喹啉类化合物，其制备方法和用途
JP2023507610A (ja) Ｃｄ２０６モジュレーター、その使用、および調製方法
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
KR20160087902A (ko) N-(4-((3-(2-아미노-4-피리미디닐)-2-피리디닐)옥시)페닐)-4-(4-메틸-2-티에닐)-1-프탈라진아민 염의 약제학적으로 허용가능한 결정형 및 이의 용도
WO2023116390A1 (zh) 具有mat2a抑制活性的嘧啶-2（1h）-酮并二环类化合物及其用途
CN104418867B (zh) 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
WO2023133221A2 (en) Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies
WO2018099451A1 (zh) 化合物的晶型
CN105481835B (zh) 一种喹唑啉衍生物lu1508及其制备方法和应用
WO2024140754A1 (zh) 一种萘酰胺类化合物、其制备方法及其应用